Lupin rolls out generic oncology drug in US market

New Delhi: Drug firm Lupin on Monday said it has launched a generic cancer treatment medication in the US.

The company has launched Dasatinib Tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the US, following the approval from the US Food and Drug Administration (USFDA).

The product was developed in partnership with Pharmascience Inc, it added. Dasatinib Tablets are bioequivalent to Sprycel Tablets of Bristol-Myers Squibb Company, and indicated for the treatment of the newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase.


As per the IQVIA MAT Oct 2025 sales data, Dasatinib Tablets had an estimated annual sale of USD 930 million in the US.

Lupin shares were trading 0.55 per cent down at Rs 2,126.80 apiece on the BSE.